# A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment

> **NCT00809796** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oncozyme Pharma Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** pentamidine

## Key facts

- **NCT ID:** NCT00809796
- **Lead sponsor:** Oncozyme Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2011-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00809796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00809796, "A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00809796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*